グループリーダー：加藤 正樹
うつ病・双極性障害の治療エビデンスの蓄積と治療精度の向上、プレシジョンメディスンの実現のためのアルゴリズムの構築を目指した研究グループです。
難治性や、再燃予防、副作用予防などの治療に有用なゲノムやバイオマーカー、背景因子などの探索を行っております。薬物治療以外にも、ニューロモデュレーション(ｍECTやrTMS)、マインドフルネスやリワークなどの介入との関連研究も行っております。
メタ解析を用いて、様々な臨床疑問の答えを導きだす研究も行っております。うつ病や双極性障害のガイドラインに中心的に関わる活動も行っております。
グループの主な業績
- Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis. Transl Psychiatry. 2024;14:296.
- Effectiveness and changes in brain functions by an occupational therapy program incorporating mindfulness in outpatients with anxiety and depression: a randomized controlled trial. Neuropsychobiology. 2023
- Relationship between circulating mitochondrial DNA and microRNA in patients with major depression. J Affect Disord. 2023;339:538-546.
- Characteristics of persistent depression in the long-term: Randomized controlled trial and two-year observational study. Heliyon. 2023;9:e20917.
- Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study. Psychiatry Clin Neurosci. 2023.
- Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial. Psychiatry Clin Neurosci. 2023.
- The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials. J Affect Disord. 2023.
- Appropriate duration of antidepressant medications for prevention of depressive relapse and the impact of life stage. Mol Psychiatry. 2023.
- Systematic Review and Meta-Analysis of Augmentation Therapy Versus Monotherapy from the Perspective of Time to the Onset of Treatment Effects. Int J Neuropsychopharmacol. 2022.
- Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. J Affect Disord. 2022;314:27-33.
- Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. International Journal of Molecular Sciences. 2022;23:3873.
- Pretreatment plasma cytokine levels as potential predictors of short-term remission of depression. World J Biol Psychiatry. 2022:1-25.
- Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science. 2021.
- Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26:118-133.
- Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis. Journal of Psychiatric Research. 2020;129:160-167.
- Clinical features related to rapid cycling and one-year euthymia in bipolar disorder patients: A multicenter treatment survey for bipolar disorder in psychiatric clinics (MUSUBI). J Psychiatr Res. 2020;131:228-234.
- Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. Journal of Psychiatric Research 2017
- Polymorphism of rs3813034 in serotonin transporter gene SLC6A4 is associated with the SSRI/SNRI response in depressive disorder: sequencing analysis of SLC6A4 Journal of Clinical Psychopharmacology 2016
- Genetic variants in combination with early partial improvement as clinical utility predictor of treatment outcome in major depressive disorder. – The result of two pooled RCT – Translational Psychiatry 2015
- The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Translational Psychiatry , 2015
- Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression.Psychiatry Res. 2012
- Review and Meta-Analysis of Antidepressant Pharmacogenetic Findings in Major Depressive Disorder, Mol Psychiatry 2010
- Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. Eur Neuropsychopharmacol. 2009
- ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008
- Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007
- Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005